These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23885696)

  • 41. Expert consensus on scientific evidence available on the use of botulinum toxin in overactive bladder.
    Esteban M; Salinas J; Arlandis S; Díez J; Jiménez M; Rebassa M; Angulo JC
    Actas Urol Esp; 2014 May; 38(4):209-16. PubMed ID: 24439057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Electrical and mechanical office-based neuromodulation.
    Kacker R; Lay A; Das A
    Urol Clin North Am; 2013 Nov; 40(4):581-9. PubMed ID: 24182977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
    Chen HW; Bercik RS; Werner EF; Thung SF
    J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update in the treatment of male urinary incontinence.
    Bing MT; Uhlman MA; Kreder KJ
    Curr Opin Urol; 2013 Nov; 23(6):540-4. PubMed ID: 23945475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overactive bladder - 18 years - Part II.
    Truzzi JC; Gomes CM; Bezerra CA; Plata IM; Campos J; Garrido GL; Almeida FG; Averbeck MA; Fornari A; Salazar A; Dell'Oro A; Cintra C; Sacomani CA; Tapia JP; Brambila E; Longo EM; Rocha FT; Coutinho F; Favre G; Garcia JA; Castano J; Reyes M; Leyton RE; Ferreira RS; Duran S; Lopez V; Reges R
    Int Braz J Urol; 2016; 42(2):199-214. PubMed ID: 27176185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pediatric overactive bladder syndrome: pathophysiology and management.
    Franco I
    Paediatr Drugs; 2007; 9(6):379-90. PubMed ID: 18052408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical pharmacology of the medical treatment for overactive bladder in adults.
    Mostafaei H; Shariat SF; Salehi-Pourmehr H; Janisch F; Mori K; Quhal F; Hajebrahimi S
    Expert Rev Clin Pharmacol; 2020 Jul; 13(7):707-720. PubMed ID: 32500759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging treatments for urinary incontinence.
    Polland A; Mock S; Dmochowski RR
    Expert Opin Emerg Drugs; 2014 Jun; 19(2):281-90. PubMed ID: 24624940
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.
    Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P
    J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The management of overactive bladder refractory to medical therapy.
    Robinson D; Giarenis I; Cardozo L
    Maturitas; 2013 May; 75(1):101-4. PubMed ID: 23415926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current and emerging investigational medical therapies for the treatment of overactive bladder.
    Tiwari A; Naruganahalli KS
    Expert Opin Investig Drugs; 2006 Sep; 15(9):1017-37. PubMed ID: 16916270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medical treatment of overactive bladder: an overview.
    Gupta K; Kaushal S
    Curr Clin Pharmacol; 2012 Aug; 7(3):229-39. PubMed ID: 22564120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy.
    Ridout AE; Yoong W
    J Obstet Gynaecol; 2010 Feb; 30(2):111-4. PubMed ID: 20143965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder.
    Chung E; Lee D; Gani J; Gillman M; Maher C; Brennan J; Johns Putra L; Ahmad L; Chan LL
    Med J Aust; 2018 Jan; 208(1):41-45. PubMed ID: 29320672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Practice Patterns for Women With Overactive Bladder Syndrome: Time Between Medications and Third-Line Treatments.
    Kirby AC; Park S; Cook SB; Odem-Davis K; Gore JL; Wolff EM
    Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):431-436. PubMed ID: 32265405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overactive Bladder in Frail Older Adults.
    Shaw C; Wagg A
    Drugs Aging; 2020 Aug; 37(8):559-565. PubMed ID: 32557178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.